Tekla Capital Management LLC Affimed N.V. Call Options Transaction History
Tekla Capital Management LLC
- $2.53 Billion
- Q2 2023
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding AFMD
# of Institutions
3Shares Held
1.09MCall Options Held
0Put Options Held
0About Affimed N.V.
- Ticker AFMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 149,339,008
- Market Cap $391M
- Description
- Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...